Diabetes Antibody Standardization Program: Evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2

Unit for Diabetes and Coeliac Disease, Institution of Clinical Sciences, Clinical Research Centre, University Hospital MAS, Malmö, Sweden.
Diabetologia (Impact Factor: 6.67). 05/2008; 51(5):846-52. DOI: 10.1007/s00125-008-0967-2
Source: PubMed


Islet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002--2005).
Up to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9-35 years) and 100 blood donor controls. Results were analysed using receiver operator characteristic (ROC) curves with sensitivity adjusted to 95% specificity in workshop controls.
GADA assays performed well in all three workshops (median area under the ROC curve [AUC] 0.94; interquartile range 0.91-0.95) and performance was similar to DASP 2000. Performance of IA-2A assays improved over the workshop programme. Median AUC was 0.81 (interquartile range 0.79-0.83) in DASP 2002, 0.82 (interquartile range 0.78-0.84) in 2003, and 0.85 (interquartile range 0.82-0.87) in 2005 (p < 0.0001). Performance of GADA ELISA improved between 2002 and 2005, and, in DASP 2005, achieved higher median AUC and adjusted sensitivity than RIA. IA-2A ELISA improved and, in DASP 2005, achieved AUCs equivalent to in-house RIA. Assays using IA-2ic or full length IA-2 clones were more sensitive than those using IA-2bdc, with higher AUC (p = 0.004).
GADA and IA-2A assays perform well in discriminating health and disease. The workshop format highlights systematic differences related to assay method and allows full evaluation of novel methods. The programme of autoantibody workshops in type 1 diabetes provides a model for other autoimmune diseases.

Full-text preview

Available from:
  • Source
    • "Autoantibodies to GAD65 (GADA) and IA-2 (IA-2A) were measured by precipitation of in vitro transcribed and translated GAD65 or IA-2, biosynthetically labeled with[35S]methionine. Specificity and sensitivity in the Diabetes Autoantibody Standardization Program (DASP)[19]was 76 and 94% for GADA and 72 and 100% for IA-2A, respectively . Insulin autoantibodies (IAs) were measured by precipitation of 125I-(A14) human insulin[20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) regulate T cell development and function and the disruption of miRNAs in natural regulatory CD4+ FOXP3+ T cells (nTreg) leads to autoimmune disease in mice. To investigate miRNA expression in relation to autoimmune disease risk in humans we sequenced them in purified CD4+ T cell subsets from individuals at high risk of type 1 diabetes (pre-T1D), as well as other healthy individuals. Differences in miRNA expression patterns were observed between specific T cell subsets and, within subsets, between pre-T1D and healthy individuals. Compared to healthy, naive CD4+ T cells in pre-T1D displayed 32 differentially expressed miRNAs, potentially a template for altered miRNA expression in effector memory T cells in T1D. Naive nTreg in pre-T1D displayed two differentially expressed miRNAs, Let-7c and miR-15a. In contrast, nTreg activated in vivo displayed a large number of differentially expressed miRNAs, revealing a pro-inflammatory and FOXP3-repressive signature. Differential expression of specific miRNAs was also a signpost to altered T cell function. For example, in pre-T1D, increased expression of miR-26a in nTreg activated in vivo or in vitro was associated with decreased expression of its target, the histone methyltransferase EZH2. Chemical inhibition of EZH2 decreased the number of activated naïve nTreg and their expression of nTreg signature genes FOXP3 and TIGIT. Our findings demonstrate that miRNAs differentially expressed in CD4+ T cell subsets are markers of risk and T cell dysfunction in T1D.
    Full-text · Article · Jan 2016 · Journal of Autoimmunity
  • Source
    • "GADA was identified using commercially available enzyme linked immunosorbent assay's (ELISA) from RSR Ltd. with a reported specificity and sensitivity of 100% and 90% respectively [19]. Absorbance was measured in a FLOUstar Optima (BMG Labtech). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some women with gestational diabetes (GDM) present with autoantibodies associated with type 1 diabetes. These are usually directed against glutamic acid decarboxylase (GADA) and suggested to predict development of type 1 diabetes. The primary aim of this study was to investigate if GADA IgG subclasses at onset of GDM could assist in predicting postpartum development. Of 1225 women diagnosed with first-time GDM only 51 were GADA-positive. Total GADA was determined using ELISA. GADA subclasses were determined with radioimmunoassay. Approximately 25% of GADA-positive women developed type 1 diabetes postpartum. Titers of total GADA were higher in women that developed type 1 diabetes (142.1 vs 74.2 u/mL; p=0.04) and they also had lower titers of GADA IgG4 (index =0.01 vs 0.04; p=0.03). In conclusion we found that that women with high titers of total GADA but low titers of GADA IgG4 were more prone to develop type 1 diabetes postpartum.
    Full-text · Article · Nov 2015 · Clinical Immunology
  • Source
    • "One of the current methods for the detection of IA-2As is radioimmunoassay (RIA), which is based on immunoprecipitation of 125I- or 35S-methionine-labeled recombinant IA-2 (intracellular portion) [9], [10]. Although several IA-2 RIAs have been reported to achieve high levels of sensitivity and specificity [11], they are expensive and usually take more than 24 h to carry out. In addition, they have the disadvantage of requiring special precautions and licensing because radioactive isotopes are used. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes (T1D) results from the destruction of pancreatic insulin-producing beta cells and is strongly associated with the presence of islet autoantibodies. Autoantibodies to tyrosine phosphatase-like protein IA-2 (IA-2As) are considered to be highly predictive markers of T1D. We developed a novel lateral flow immunoassay (LFIA) based on a bridging format for the rapid detection of IA-2As in human serum samples. In this assay, one site of the IA-2As is bound to HA-tagged-IA-2, which is subsequently captured on the anti-HA-Tag antibody-coated test line on the strip. The other site of the IA-2As is bound to biotinylated IA-2, allowing the complex to be visualized using colloidal gold nanoparticle-conjugated streptavidin. For this study, 35 serum samples from T1D patients and 44 control sera from non-diabetic individuals were analyzed with our novel assay and the results were correlated with two IA-2A ELISAs. Among the 35 serum samples from T1D patients, the IA-2A LFIA, the in-house IA-2A ELISA and the commercial IA-2A ELISA identified as positive 21, 29 and 30 IA-2A-positive sera, respectively. The major advantages of the IA-2A LFIA are its rapidity and simplicity.
    Full-text · Article · Jul 2014 · PLoS ONE
Show more